#FDAapproves treatment for newly diagnosed patients with light chain (AL) amyloidosis: https://t.co/ajIOSxFsX6 https://t.co/lIB8ucQuI8

We’re working with drug application holders to remove instructions for preparation of these drugs by syringe and to recommend preparation in intravenous infusion bags only.

FDA alerts HCPs to labeling updates for the preparation of vinca alkaloids, a group of chemotherapy agents, to reduce the potential for unintended spinal administration, which causes death or severe neurological injury: https://t.co/i1y8W2RkfR. View PI: https://t.co/OQZilySDD8 https://t.co/M5jRgILvvO

#FDAapproves treatment for certain adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma: https://t.co/KuvCyNdhWL https://t.co/bEpRWt90SL

FDA issues guidance to help generic drug applicants in ensuring the protection of participants resuming or initiating bioequivalence (BE) studies conducted to support the approval of an ANDA that has been disrupted during #COVID19: https://t.co/Ay06sXCoGq https://t.co/1kg2o6ga67

#FDAapproves treatment for pediatric patients 1 year of age and older and young adults with a certain type of relapsed or refractory systemic lymphoma: https://t.co/eT1fE8YBte https://t.co/H6u2eC2gMw

ICYMI: #CDERSBIA webinar on Regulatory Perspectives for Development of Drugs for Treatment of Non-alcoholic Steatohepatitis on Jan 29 at 1 PM EST. Register: https://t.co/0VF9FowINe https://t.co/trG8qZpdNp

FDA issues guidance to describe methods to ensure the potency of monoclonal antibodies and other therapeutic proteins proposed for use as anti-infective agents for #COVID19: https://t.co/fenLKIRqhQ https://t.co/TiBpZjg70a

FDA’s Pandemic Recovery and Preparedness Plan initiative strengthens ongoing #COVID19 pandemic response and our resiliency for future public health emergencies. Find out more in #FDAVoices. https://t.co/qeLUPBVjv1

New Drug Trials Snapshot available for Ebanga (ansuvimab-zykl): https://t.co/YmWOwpmQrg https://t.co/F1L0GK1FQ5

If a prescription drug sounds too good to be true, it might just be. Learn about recognizing and reporting potentially false or misleading prescription drug promotion with FDA’s Bad Ad Program and its free 1-hr CE course: https://t.co/JHYqwQT67y #FDABadAd https://t.co/BNSRKW0NYD

REMINDER: The application deadline for the Translational Science Interagency Fellowship is quickly approaching! Apply by Jan 15, 2021 to be considered for this 3 year fellowship: https://t.co/vgfx9ivOSp https://t.co/KbEqsnBRME

Join us on Feb 2-3 for a virtual public meeting to provide input on the scientific and ethical issues that surround the inclusion of pregnant women in clinical trials for drug development. Register: https://t.co/AZDgu6RKy4 https://t.co/814O2UYLTB

National Pharmacists Day is January 12 so make sure to thank yours for helping keep you healthy. They are on the front lines educating you on how to safely take medicines, like tranquilizers featured in this PSA. #FDAhistory #TuesdayThoughts https://t.co/W42YpeffsQ

Happy #NationalPharmacistDay! Thank you to our FDA pharmacists and pharmacists across the nation who work tirelessly to keep our communities healthy. https://t.co/uGuly5cTyJ

Join FDA and @DukeMargolis for a virtual workshop on Feb 16-17 focused on evaluating real-world evidence (RWE) from observational studies to inform regulatory decision-making. Register: https://t.co/PmKIbw6qSu https://t.co/7iaEO5qFoa

Today, we issued the Focus Areas of Regulatory Science report, which outlines areas of research that are organized by my strategic initiatives that I shared at the beginning of last year. https://t.co/2PxfdFqsRJ https://t.co/IUHVjCYYG0

New Drug Trials Snapshot available for Gemtesa (vibegron): https://t.co/FqK59FDFeW https://t.co/ZUptrdaDba

HCPs: Learn practical information on using biosimilar products and pharmacy substitution during a free webinar with CE credit on Jan 19 at 1PM ET. Register: https://t.co/Uq1s1C1jYU https://t.co/mtPWNywSju